Independent insurance agency providing property, casualty, liability, life, surety bonds, and group insurance for personal and commercial clients.
MidCap Advisors works with lower middle-market businesses and their owners during pivotal moments that influence long-term direction and value. We provide independent guidance rooted in experience, judgment, and a clear understanding of how decisions today affect outcomes over time.
Successful outcomes involve more than financial considerations alone. They reflect priorities related to leadership, continuity, risk, and legacy. We help clients weigh these factors carefully and move forward with clarity and intention.
Our team has deep experience working within lower middle-market businesses across a range of industries and situations. That background informs how we engage with owners and leadership teams and allows us to bring practical perspective to complex decisions.
Many members of our team are former operators in the industries we serve. We have built, grown, and run businesses ourselves. That experience shapes how we evaluate opportunities, manage risk, and think about execution. It keeps our work focused on what actually works in practice, not just in theory.
We operate across the full lifecycle of a transaction. We advise business owners on sell-side mergers and acquisitions, support buyers through diligence and consulting, and invest our own capital. Having experience as advisors, investors, and operators allows us to anticipate challenges early and guide decisions with a broader perspective.
We invest time at the outset to understand each business at no cost, ensuring the engagement is the right fit. That early work allows us to be prepared, aligned, and thoughtful before decisions are made. Our team remains focused on helping owners make informed choices that support their business, their family, and their long-term goals.
Just like in your business, our people are what make us great
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
NEW YORK, NY – July 29th, 2026 – MidCap Advisors, a leading lower-to middle-market investment bank, announced its role as the exclusive financial
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
Our Vice President, Tony Leonard, was recently quoted in a Wealth Solutions Report article.
Tony addresses how a financial advisor can help their business owner clientele when succession through M&A is a priority. With a CPA, an attorney, a financial advisor, and an experienced investment banker who can provide end-to-end guidance, these parties can supply business owners with the appropriate resources and advice. Together they will ensure a timely and successful closing of their client’s company.
Our Vice President of Healthcare, Our Team, was featured in a Healthcare Business International article that further speculated about Fresenius’ strategy to offload its expansive fertility asset, The Eugin Group, to the M&A market. It is through the courtesy of Healthcare Business International that we can share this information with our audience.
Robert shared insights related to The Eugin Group’s partnerships with prominent IVF clinics across 3 continents, he assessed the overall U.S. M&A market, and he explained the market from an investor’s perspective. Also, with experience as an administrator and CEO of a hospital, Robert observed that even though European hospitals are selling “non-core” fertility assets, U.S. hospitals are not doing the same currently. Robert cited higher concentrations of older patients with critical needs, nurse shortages, and wage demands as possibilities for why hospitals would need liquidity.
Currently in its 90th year of operation, PMA provides commercial and personal lines customers risk management solutions.
“EMG retained MidCap to identify a qualified buyer with the ideal cultural fit while maximizing enterprise value,” said Douglas Hendrickson, Partner at MidCap, who led the deal team along with MidCap Vice Presidents Brandon Bisack and Michael Gorlick, and Analyst Gabriella Walker. “The ideal buyer had to respect EMG’s entrepreneurial vision to operate independently and retain its full staff while availing itself of the advanced technological resources and elevated marketing opportunities an acquisition could provide. SMS checked all the boxes.”
SMS represents top Medicare Supplement, Medicare Advantage, annuity, life, long-term care, and travel insurance in all 50 states. The firm was founded in 1982 and joined parent firm Alliant Insurance Services in 2020.
Value Is Created Before the Process Begins: One of the most consistent findings in healthcare M&A is that the practices that achieve the highest valuations are those that invested meaningful time and resources in pre-sale preparation, often 18 to 36 months before formally entering a process. The moment you engage with potential buyers, the narrative is largely set. The financial statements are what they are; the operational profile is established; the payer contracts are in place. Buyers will underwrite what they observe. The highest-leverage moment to influence your valuation outcome is before the process begins, not during it.
The first and most foundational step in pre-sale preparation is establishing clean, audit-ready financial statements. This means separating personal expenses from practice operations, normalizing owner compensation to fair market value, documenting all add-backs with supporting receipts and explanations, and ensuring that your chart of accounts clearly reflects the practice’s underlying economics.
Revenue cycle optimization is one of the most direct paths to EBITDA improvement, and therefore to higher valuation. Practices that reduce claims denial rates, accelerate collections, and eliminate coding errors can capture meaningful incremental revenue without adding clinical volume. Similarly, supply chain renegotiation, staffing ratio optimization, and overhead cost reduction can each add meaningful basis points to EBITDA margins. Practices represented by M&A advisors or investment banks achieved, on average, a 25% higher multiple from buyers, a premium largely attributable to pre-market optimization and competitive process management.
Buyers evaluate practices not just as financial assets but as operating businesses that must continue to generate earnings after closing. A practice where all clinical leadership and patient relationships are concentrated in one or two founding physicians presents a concentration risk that buyers will discount. Building a second tier of physician leadership with younger partners who have long-term agreements, administrative responsibilities, and demonstrated patient loyalty is one of the most durable value creation strategies available to OB/GYN practice owners. This process takes time, which is why starting early matters.
Buyers pay for future earnings, not just historical performance. A practice that can articulate a credible, data-supported growth narrative, whether through geographic expansion, service line addition, provider recruitment, or payer contract improvement, will consistently achieve higher valuations than a comparable practice with no visible growth pathway. Work with your advisors to build a coherent growth model grounded in realistic assumptions and supported by documented market data. This narrative serves as the foundation of the Confidential Information Memorandum (CIM), which drives buyer interest and competitive tension in a formal sale process.
An Investment Thesis Built on Fundamentals: Private equity firms do not allocate capital based on sentiment. They follow predictable, scalable cash flows, recurring revenue, and addressable markets large enough to support platform growth. Women’s health checks every one of those boxes. The global women’s health services market was valued at approximately $41.5 billion in 2022 and is projected to grow at more than 5% annually by 2030. The U.S. OB/GYN services segment alone encompasses a fragmented landscape of thousands of independent practices serving tens of millions of patients, exactly the kind of market structure that private equity consolidation strategies are designed to exploit.
Unlike many healthcare specialties where patient encounters are episodic, OB/GYN practices benefit from long, longitudinal patient relationships. A woman’s relationship with her OB/GYN often begins in early adulthood with preventive and contraceptive care and continues through pregnancy, postpartum care, perimenopause, and beyond. This lifecycle engagement creates a highly predictable revenue base that PE underwriters value. Women visit doctors approximately 33% more frequently than men, generating substantial additional healthcare spending, according to AMB Wealth’s OB/GYN Industry Primer. That recurring, high-frequency visit pattern supports the kind of steady EBITDA generation that private equity sponsors rely on when modeling returns.
Beyond core obstetrics and gynecology, women’s health platforms offer compelling cross-sell opportunities. Platforms are increasingly integrating labs, fertility services, aesthetic medicine, menopause care, behavioral health, and mammography into their service portfolios. According to Physician Growth Partners’ Q1 2025 white paper on women’s health private equity, practices offering ancillary services such as fertility treatment, mammography, and menopause care are experiencing accelerated consolidation activity. The Medical Group Management Association (MGMA) has found that practices that integrate ancillary services generate 15% to 25% higher net revenue per provider than those that do not. For a private equity sponsor underwriting a multi-year hold, each new service line represents both incremental EBITDA and a higher exit multiple.
Demand for OB/GYN services is structurally growing. The average maternal age rose from 23.7 in 1985 to 29.6 in 2024, according to Cascade Partners, driving greater complexity and physician oversight requirements for an increasing share of pregnancies. Meanwhile, the supply side is constrained: the U.S. Health Resources & Services Administration projects a shortage of nearly 9,900 OB/GYNs by 2037. The combination of rising demand and constrained supply creates a durable pricing environment—a dynamic PE investors price favorably in their underwriting models. Over 500 hospitals have closed their obstetric units since 2010, accelerating patient migration to independent and consolidated practices.
With nine major platforms now operating and more capital seeking entry, well-positioned independent practices represent valuable acquisition targets in an increasingly competitive market.
A Market in Motion: The women’s health sector has been one of the most actively consolidated corners of U.S. healthcare for more than a decade. What began as a handful of pioneering transactions in 2013, when Ares Management partnered with Unified Women’s Healthcare to form the first dedicated women’s health platform, has since grown into a robust, competitive landscape featuring nine major private equity-backed platforms operating nationwide. Despite a broader cooling in physician practice M&A volume in 2024, women’s health deal activity remained notably resilient, reflecting continued investor confidence in the specialty’s demographic tailwinds and its capacity for service-line expansion.
According to industry data compiled by Irving Levin Associates, physician practice management transactions declined approximately 14% year-over-year in 2024, with 473 deals completed compared to 537 in 2023. Yet women’s health bucked this broader trend. Key platforms dominating recent activity include Altas Partners and Ares Management (Unified Women’s Healthcare), Shore Capital Partners (Together Women’s Health), BC Partners (Women’s Care Enterprises), Partners Group (Axia Women’s Health), LightBay Capital (Femwell/VitalMD), and Webster Equity Partners (Nova Women’s Health Partners), among others, each continuing to build regional density in concentric markets across the Northeast, Southeast, Midwest, and Southwest. Notably, Axia Women’s Health—formed by Audax Private Equity in 2017 and sold to Partners Group in 2021 in a transaction reported at approximately $800 million, completed 18 add-on acquisitions under Audax alone and remains one of the most acquisitive platforms in the space. Most recently, Nova Women’s Health Partners emerged as the ninth major platform through a late-2024 partnership between WomanCare and Women’s HealthFirst, backed by Webster Equity Partners.
Private equity remains the dominant buyer in physician practice M&A, representing more than 90% of transactions. For OB/GYN practices in 2025, add-on acquisitions, the most common transaction type for independent practices, typically transact at mid-single-digit EBITDA multiples, while platform-ready groups with $5 million or more in normalized EBITDA can command multiples of 10x to 14x. The platform premium is real: practices that cross key EBITDA thresholds, have diversified service lines, and have strong management infrastructure can transition from add-on candidates to platform anchors, earning a 4- to 6-turn premium in the process.
The consolidation wave has important strategic implications for independent OB/GYN owners. As platforms grow larger and their geographic footprints expand, competition for clinical talent intensifies, referral dynamics shift, and payer negotiations increasingly favor larger entities. Physician prices for childbirth services in OB/GYN rose by approximately 15% following consolidation, according to research cited by Becker’s Healthcare, illustrating the pricing leverage that scale confers. Independent practices that delay evaluating their strategic options risk finding themselves at a competitive disadvantage as local markets reach saturation, or alternatively, missing the window of maximum investor interest. Understanding the M&A landscape is no longer optional for OB/GYN owners. It is a strategic imperative.
Heading into 2026, healthcare M&A deal value and volume are expected to strengthen, according to PwC’s annual health industries outlook. For OB/GYN practice owners, the question is not whether consolidation will continue but whether they are positioned to participate on favorable terms.
###
EXECUTIVE SUMMARY
The Opportunity. More than 55 million American women are in perimenopause or menopause at any given time, with 1.3 million new cases each year. Virtually all of them already have an OB-GYN. Yet 95% are never offered treatment by their physician (Boston Consulting Group (BCG) 2025), only 29% even seek care (Mayo Clinic, 2025), and 35% require four or more visits before their symptoms are correctly linked to hormonal changes. This is not a demand problem. Women are actively seeking care. The gap reflects systemic constraints in training pipelines, reimbursement structures, and visit economics that have left even motivated OB-GYNs without the time, tools, or curriculum to address menopause at scale.
The Stakes. The economic footprint is real: $26.6 billion in annual U.S. costs (Mayo Clinic, 2023), a 10% post-menopause earnings penalty for affected women (Stanford, 2025), and a $40 billion clinical market validated by BCG, PwC, and the Milken Institute. PwC projects women’s health will exceed $600 billion by 2030. Between 2020 and 2025, nearly $60 billion in private capital flowed into women’s health, and menopause is now the fastest-growing subcategory, growing at 13% annually. Every dollar of that capital flows through a gap OB-GYN practices have, highlighting the opportunity for Women’s care practices.
Why OB-GYNs Didn’t Take Advantage of Opportunity. Five structural forces explain the gap: (1) Training gaps at the residency level only 31% of OB-GYN residencies offer any menopause curriculum and just 7% of residents feel adequately prepared (ACGME does not require it); (2) Post-WHI fear, one in three residents would not prescribe HRT to an eligible symptomatic patient, despite a now-favorable risk-benefit profile for women under 60 within 10 years of onset; (3) Practice economics a 45–75 minute counseling visit cannot compete with procedural RVUs in a 12–17 minute visit schedule; (4) Workforce shortage national OB-GYN demand is already underserved, with a projected shortfall of ~7,800 physicians by 2037 and 10.1 million women in OB-GYN deserts; (5) Cultural framing — menopause has been treated as a lifecycle inevitability rather than a clinical condition, so patients learn not to ask and providers learn not to probe.
Why Now. Six forces have converged: rehabilitated HRT evidence, the first new non-hormonal drug class in 20 years (Astellas’ Veozah, FDA-approved May 2023), mainstream cultural destigmatization, a $50M federal CARE research initiative, employer benefit adoption tripling from 4% to ~12% (Mercer, 2022–2024), and post-COVID telehealth infrastructure operating at scale (Midi Health serves 20,000 women per week).
Who Is Filling the Vacuum. Six categories of non-OB-GYN players are capturing the unmet demand: PE-backed OB-GYN platforms (Unified, Together, Axia, and Advantia), digital health and telehealth startups (Midi, the first menopause unicorn at $1B+ valuation in Feb 2026; Hims & Hers; Evernow; Maven), consumer CPG brands (Bonafide acquired by Pharmavite for $425M; now on Target shelves), employer benefit platforms (Maven, Progyny, and Carrot, distributing care to 30M+ employees), and pharmaceutical companies. A countermovement of MSCP-certified OB-GYNs is emerging at Mayo, NYU Langone, UCLA, Northwestern, Hoag, AHN, and independent practices like Elite Gynecology & Wellness and The MP Collective, but nationally, there are only 4,100 MSCPs, meaning one menopause specialist serves 13,400 affected women.
The Path Forward. OB-GYNs hold three advantages no competitor can replicate: existing patient relationships (the affected women are already in the waiting room), a full clinical scope (only OB-GYNs can deliver HRT plus surgical, oncologic, and cardiovascular co-management), and insurance credibility. Practices that act now, pursuing MSCP certification, building dedicated appointment architecture, integrating ancillary revenue (HRT monitoring, DXA, labs), adding a telehealth layer, and joining employer benefit networks report menopause becoming a top 3 revenue line within 18–24 months. Those who wait will find the market owned by others. The $40 billion opportunity exists precisely because the specialty best positioned to serve it has been constrained from doing so at scale. Those constraints are now lifting, and the practices that move first will define the next era of menopause care.
| 55 Million U.S. Women in Perimenopause/Menopause | 95% Not Offered Treatment By Their Physician | 31% OB-GYN Programs With Menopause Training | $40B+ Market Being Captured By Non-OB-GYNs |
| 7% Residents Feel Prepared for Menopause | 35% Patients Need 4+ Visits For Diagnosis | 4,100 MSCP Certified Practitioners | 13%/yr Menopause Investment Growth Rate |
TABLE OF CONTENTS
The menopause care market is a rare convergence of a massive, underserved population (55M women), proven demand (women actively seeking care and being turned away), multiple viable business models, strong PE/VC returns, and cultural tailwinds accelerating adoption. PwC estimates women’s health will be $600B+ by 2030. Capital is not leading this market it is following a demand signal that OB-GYN practices created by not serving it
The financial commitment to the menopause market has reached an institutional scale. Between 2020 and 2025, nearly $60 billion of private capital flowed into core women’s health, and menopause is the fastest-growing investment subcategory at 13% annual growth (PwC, April 2026).
| Company / Fund | Amount | Date | Category |
| Midi Health | $60M Series B | Apr 2024 | Menopause telehealth |
| Maven Clinic | $125M Series F | 2024 | Women’s lifecycle / menopause |
| Flo Health | $200M Series C | 2024 | Women’s health app incl. menopause |
| Bonafide Health (Pharmavite acq.) | $425M acquisition | 2023 | Consumer menopause CPG |
| Evernow | $28.5M Series A | Prior 2023 | Menopause telehealth |
| Portfolia Women’s Health Fund IV | $20M fund | 2025 | Menopause + fertility + longevity VC |
| January 2026 Femtech rounds | $314M (month total) | Jan 2026 | Multiple women’s health categories |
| Menopause startups total (4 yrs) | $200M+ | 2022-2025 | Menopause-specific startups only |
| PE in OB-GYN + women’s health | $80B+ (4 yrs) | 2021-2025 | Provider platform consolidation |
Perimenopause typically begins in a woman’s early-to-mid 40s and can last 7 to 14 years before and after the final menstrual period. During this transition, women may experience more than 30 documented symptoms, including vasomotor symptoms (hot flashes, night sweats), sleep disruption, cognitive changes, mood dysregulation, genitourinary syndrome of menopause (GSM), accelerated bone density loss, cardiovascular risk escalation, and sexual dysfunction. These are not inconveniences. They are clinically significant, treatable conditions with documented long-term health consequences if left unaddressed.
| Women in Peri/Menopause (U.S.) | 55 million at any given time; 1.3 million new cases per year |
| Symptom Prevalence | 96.7% of symptomatic women report at least one symptom; 80%+ moderate-to-severe hot flashes |
| Duration of Symptoms | Average 7.4 years; up to 10+ years for vasomotor symptoms in many women |
| Women Who Seek Any Care | Only ~29% seek medical care for symptoms (Mayo Clinic study, Oct 2025) |
| Treatment offered (of those seen) | 95% NOT offered any treatment by their physician (BCG, 2025) |
| Correctly Diagnosed on First Visit | Only 25% correctly identified as perimenopausal/menopausal on the first provider visit |
| Multi-Visit Journey | 35% must see a provider 4 or more times before symptoms linked to hormonal changes |
| Currently Receiving Treatment | Only 28% of symptomatic women receive any treatment (Sanctuary Wellness Survey, 2026) |
| Economic Cost (U.S.) | $1.8B/yr lost work time; $26.6B/yr total cost including medical expenses (Mayo Clinic, 2023) |
| Earnings Penalty | Women take a 10% earnings cut in the 4 years following menopause onset (Stanford, Mar 2025) |
The Confluence of Forces:
The paradox is this: OB-GYNs are the providers best positioned by clinical training, patient relationships, and scope of practice to lead menopause care. The affected women are already in their waiting rooms. Yet women leave OB-GYN offices without diagnoses, without treatment plans, and without answers. Five structural forces explain why.
Lack of Training: Residency programs stopped teaching menopause medicine after the NIH’s 2002 Women’s Health Initiative (WHI) study, which reported increased risks of breast cancer and cardiovascular events with combined estrogen-progestin HRT, leading to a dramatic drop in hormone therapy prescribing and the near-abandonment of menopause training in OB-GYN residency programs. Two decades later, the curriculum has not been restored at a meaningful scale.
The OB-GYN Menopause Training Crisis — Residency Data
| Metric | Finding | Source | |
| Programs with ANY menopause curriculum | Only 31% | OB-GYN Residency Survey 2023 | |
| Programs with dedicated menopause clinic time | Only 29.3% | PubMed Needs Assessment 2023 | |
| Programs offering 2 or fewer lectures/year | 71% of those who teach it at all | Medical Update Online | |
| Residents who feel “adequately prepared” | Only 7% | Mayo Clinic / Axios 2025 | |
| Residents who received ZERO menopause lectures | >20% | ACOG Residency Analysis 2023 | |
| Would prescribe HRT to eligible symptomatic patient | Only 67% — 1 in 3 would not | OB-GYN Research Journal 2023 | |
| Menopause training required by ACGME | Not a required element of residency as of 2025 | ACGME Program Requirements | |
Contradictory Evidence: Even OB-GYNs with some menopause exposure carry the institutional scar of the 2002 WHI study, which generated massive publicity suggesting HRT caused breast cancer and heart attacks. The nuance that newer formulations in women under 60, initiated within 10 years of menopause onset, have a strongly favourable risk-benefit profile was never effectively communicated back to the medical community. In 2023, one-third of OB-GYN residents said they would NOT prescribe hormone therapy to a symptomatic, eligible patient. Women arrive asking for help and are turned away by physicians trained to fear the most effective treatment available. This physician-level avoidance is a primary reason telehealth startups (whose entire clinical model centres on HRT expertise) have been so successful.
Practice Model: Practices are financially engineered around high-revenue procedural service deliveries, C-sections, and laparoscopies. Menopause management is a 45-75 minute cognitive, counselling-intensive visit that codes as a standard E/M. A busy practice with a full obstetric panel faces direct revenue cannibalization when dedicating slots to menopause management.
Workforce Shortage: No Capacity to Expand
| OB-GYN Supply vs. Demand (2025) | Only 93.4% of national demand being met — already in deficit (HRSA 2025) |
| Projected Shortage by 2037-38 | 7,660–7,980 OB-GYN shortage (HRSA Workforce Report 2025) |
| Women in OB-GYN Deserts | 10.1 million U.S. women in counties with NO OB-GYN |
| Burnout | ~30% of OB-GYNs report clinical burnout; 40% say work-life balance worsened |
| Average Visit Duration | 12-17 minutes per OB-GYN visit — inadequate for comprehensive menopause intake |
The Stigma and Normalization Gap: Menopause has been framed as a lifecycle inevitability to endure rather than a clinical condition to be treated. The annual well-woman visit is designed for screening and prevention — not chronic condition management. When a woman brings up hot flashes in a 15-minute well-woman visit, the provider has no protocol, no time, and often no training. Women learn not to ask. Providers learn not to probe.
A meaningful countermovement is underway. A growing cohort of OB-GYNs in academic medical centres, independent practices, and PE-backed platforms has identified menopause medicine as a clinical and business imperative and is building dedicated programs. These early movers are the template for what the broader speciality must do.
The MSCP Certification Movement: The MSCP credential — offered through The Menopause Society since 2002 — has become the primary signal of clinical expertise in menopause. MSCP growth is the most meaningful organized response to the OB-GYN training gap.
| Current MSCPs (2025) | 4,100 certified practitioners — up from ~1,000 a decade ago (AAMC, 2025) |
| The Access Gap | 4,100 MSCPs for 55 million affected women = 1 specialist per 13,400 women — massive white space |
| Exam Windows | Offered June and October annually; $400 for Menopause Society members / $725 non-members |
| NextGen Now Initiative | $10M Menopause Society program targeting 25,000 healthcare professionals with training + scholarships |
| Business Impact | MSCP practices report more referrals, stronger differentiation, and premium patient satisfaction within 12 months |
Dedicated Menopause Programs Launching Nationally:
| Institution | Program | Launch | Model |
| Mayo Clinic (Jacksonville) | Women’s Health Specialty Clinic | 2024-2025 | MSCP-led dedicated menopause clinic |
| NYU Langone Health | Center for Midlife Health and Menopause | 2024-2025 | Multidisciplinary; endo + GYN + mental health |
| UCLA Health | Comprehensive Menopause Program | 2024-2025 | Integrated care; PCPs/OB-GYNs trained to expand network |
| Northwestern Medicine | Center for Sexual Medicine and Menopause | Established | Reproductive endo + pelvic pain + vulvovaginal specialists |
| Hoag Health (Newport Beach) | Hoag Menopause Program | Oct 2025 | Interdisciplinary MSCP-led; endocrinology + GYN + mental health + diet + sleep |
| AHN (Allegheny Health Network) | Midlife Women’s Associates | 2025 | 4 physicians + 2 NPs exclusively for midlife women; extended visits |
| Maimonides Women’s Health | Menopause Center (Brooklyn’s first) | Late 2025 | Hospital-based; MSCP-certified staff; self-referral accepted |
| St. Joseph’s Health (Syracuse) | Physicians Menopause Clinic | Apr 2026 | Dr. Madison Healey MSCP; whole-person care; community access |
| Walter Reed NMMC | Women’s Midlife Telehealth Clinic | Jun 2024 | Virtual; MSCP-led; 60-min intake; first military menopause clinic |
The early mover advantage: OB-GYN practices that earn MSCP certification, create dedicated appointment structures, and build ancillary revenue streams (HRT monitoring, labs, bone density, and supplements) report that menopause services become a top-3 revenue generator within 18-24 months. Patient panels, referral networks, and brand equity built now will be very difficult for later entrants to displace.
In the absence of adequate OB-GYN menopause care, six categories of players have built organizations, products, and services to capture the unmet demand. Each brings distinct competitive advantages and vulnerabilities.
PE-Backed OB-GYN Platforms:
| Platform | Menopause Strategy | Key Asset |
| Unified Women’s Healthcare | Gennev (all-50-state virtual menopause platform); Gennev feeds digital-to-physical conversion | 2,700 providers; 4.5M visits/yr; Gennev national brand |
| Together Women’s Health | True. Women’s Health digital partnership; membership concierge menopause | 230+ locations; 9 states; white-label virtual |
| Axia Women’s Health | Embedded menopause; Cigna/BCBS VBC contracts drive proactive screening | 600K patients; insurance incentivizes proactive meno ID |
| Advantia Health | Women’s Health Hub model; OB-GYN + primary + mental health + menopause | Pacify digital: 63+ service types; most vertically integrated |
| Nova Women’s Health Partners | HRT/menopause labs built in as Day-1 ancillary revenue | Webster Equity; the newest built from menopause-up |
| Women’s Care | Ancillary HRT; FL/AZ/TX sunbelt density; near PE exit | BC Partners; ~1M visits/yr; $2.5-3.5B est. value |
Digital Health & Telehealth Startups:
Consumer & CPG Brands: Pharmavite’s $425M acquisition of Bonafide Health (2023) validated the non-prescription menopause consumer market at an institutional scale. The September 2025 target launch placed Bonafide on mainstream retail shelves for the first time — completing the transition from speciality to mainstream consumer health. Key players: Bonafide (Pharmavite, $425M), Health & Her (6,000+ CVS stores), Kindra, Stripes (Naomi Watts), Womaness (Unilever Ventures).
Employer Benefit Platforms: Employer adoption of menopause benefits tripled among large employers from 4% (2022) to ~12% (2024) (Mercer). Maven Clinic (23M employees), Progyny (7.2M employees), and Carrot Fertility (4M+ employees) are competing for employer contracts – distributing menopause care through the HR benefits channel at enterprise scale.
Pharmaceutical Companies: Astellas’ Veozah (fezolinetant, FDA approved May 2023) — the first non-hormonal NK3 receptor antagonist for hot flashes — represents the most significant pharmaceutical menopause innovation in 20 years. At $550/month, it opens care for the estimated 15-20 million women who cannot safely use estrogen. (Note: In December 2024, the FDA added a Boxed Warning for rare but serious hepatotoxicity; prescribers must evaluate hepatic function before and during treatment.) Established HRT makers (AbbVie, Bayer, Pfizer/Wyeth) defend existing formulary positions as newer bioidentical generics gain share.
Every barrier described in this white paper is addressable. The practices that move now will build patient panels, referral networks, and ancillary revenue that compound over time. Those that wait will find the market occupied by well-capitalized outsiders who built their models specifically because OB-GYNs did not act.
The Structural Advantages OB-GYNs Have That No Competitor Can Replicate
Six Actions for OB-GYN Practices Ready to Lead
FINAL PERSPECTIVE: The $40 billion menopause market did not exist because of digital health entrepreneurs or consumer brands. It exists because 55 million American women have a clinical need and the specialty best equipped to serve it failed to do so for two decades. That can change — but only if OB-GYN practices treat menopause not as an afterthought of women’s reproductive care, but as the primary clinical opportunity of midlife women’s health. The practices that understand this now will own the market. The practices that wait will find it owned by others.
Appendix: Significant Menopause & Perimenopause Transactions (2023–2026)
The following table summarizes significant venture funding rounds, strategic acquisitions, and fund launches focused on menopause and perimenopause care from 2023 through early 2026. Menopause-focused startups raised over $200 million between 2022 and 2025 alone, and the broader femtech sector deployed approximately $530 million into menopause care from 2015 through Q1 2023, per PitchBook and Crunchbase data cited by SJF Ventures. The pace of investment has accelerated sharply: Midi Health’s $100 million Series D in February 2026 — valuing the company at over $1 billion — marked the first menopause-focused unicorn and signaled that institutional capital now views midlife women’s health as a core growth vertical, not a niche category.
| Date | Company / Fund | Transaction Type | Amount | Lead Investor / Acquirer | Significance |
| Feb 2026 | Midi Health | Series D | $100M | Goodwater Capital | First menopause-focused unicorn ($1B+ valuation); Serena Ventures, Foresite Capital, GV participated |
| Spring 2025 | Midi Health | Series C | $50M | Not disclosed | Expanded national insurance coverage to 45M+ women; added cardiology, metabolic health lines |
| Jan 2025 | Allara Health | Series B | $26M | Index Ventures | Hormonal health telehealth (PCOS, perimenopause); 4× revenue growth in 2024; GV participated |
| 2025 | Portfolia FemTech Fund IV | Fund Launch | $20M | — | Dedicated VC fund for women’s health; signals sustained LP interest in menopause vertical |
| Nov 2024 | Alloy Women’s Health | Series A | $16M | Kairos HQ | DTC menopause telehealth; expanding into hair, skin, and sexual wellness for midlife women |
| Oct 2024 | Maven Clinic | Series F | $125M | Not disclosed | Valued at $1.7B; adding menopause to fertility/maternity benefits platform for employers |
| Jul 2024 | Flo Health | Series C | $200M | Not disclosed | Period-tracking app ($1B+ valuation); expanding into perimenopause content and care for 70M users |
| Apr 2024 | Midi Health | Series B | $60M | Emerson Collective | Included celebrity SPV (Sheryl Sandberg, Amy Schumer); hired 150+ clinicians |
| Sep 2025 | Evela (Berlin) | Pre-Seed | €2M | Not disclosed | B2B menopause workplace benefit platform; first institutional round |
| May 2025 | Valerie (London) | Pre-Seed | £514K | Not disclosed | Perimenopause nutrient supplement brand; earliest-stage dedicated meno investment in UK |
| 2023 | Bonafide Health / Pharmavite | Acquisition | $425M | Pharmavite (Otsuka) | Largest menopause-focused M&A to date; nutraceutical brand for menopause symptoms |
| Ongoing | Evernow | Series A | $28.5M | DCVC | DTC menopause telehealth; notable angels include Gwyneth Paltrow, Drew Barrymore, Cameron Diaz |
Sources: PitchBook company profiles; SJF Ventures / PitchBook landscape analysis (2023); Fierce Healthcare; TechCrunch; Business Wire; Fortune; New Market Pitch Femtech Funding Trends (2026). Deal values as publicly disclosed; some round sizes are approximate.
Key trend: Capital concentration is notable. Midi Health alone has raised over $250 million to date, accounting for nearly half of all dedicated menopause-care venture funding since 2015. Meanwhile, strategic acquirers are entering the space. Pharmavite’s $425 million acquisition of Bonafide Health in 2023 remains the largest menopause-focused M&A transaction on record. The emergence of dedicated fund vehicles (Portfolia FemTech Fund IV) and the entry of growth-stage investors (Goodwater, Foresite, Index Ventures) into menopause deals suggest the sector is transitioning from early-stage experimentation to institutional-scale deployment.
